Pneumococcal conjugate second or third-dose vaccines (PCVc) in Tunisia
Tunisia: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 96.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Tunisia, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Tunisia is 96.0%, measured in 2025.
That represents a change of down 1.0% on the previous year and up 10.3% over five years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Tunisia peaked at 98.0% in 2022 and was at its lowest, 0.0%, in 2008.
That places Tunisia 27th out of 194 countries with data for 2025, putting it in the top quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Tunisia, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 0.0% | — |
| 2017 | 0.0% | — |
| 2018 | 0.0% | — |
| 2019 | 0.0% | — |
| 2020 | 87.0% | — |
| 2021 | 96.0% | +10.3% |
| 2022 | 98.0% | +2.1% |
| 2023 | 97.0% | -1.0% |
| 2024 | 97.0% | +0.0% |
| 2025 | 96.0% | -1.0% |
Tunisia compared with similar countries
- Tunisia's 96.0% is above the median for lower middle income countries, which is 84.0%, 1.1× the median. (47 countries reporting)
- Tunisia's 96.0% is above the median for Middle East, North Africa, Afghanistan & Pakistan, which is 91.0%, 1.1× the median. (23 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 0.0% | 0.0% | 0.0% | 10 |
| 2020s | 95.2% | 87.0% | 98.0% | 6 |
Countries ranked near Tunisia
More health data for Tunisia
- Un projection of annual infant deaths, annual growth rate -1.68 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.2883 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,287 deaths per 1,000 people (2090)
- Number of infants who die before age 1 117 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -3.64 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.033 units per person (2025)
- Population ages 00-04, male, annual growth rate -3.77 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Tunisia?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Tunisia was 96.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Tunisia?
- The highest recorded value was 98.0% in 2022.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Tunisia?
- The lowest recorded value was 0.0% in 2008.
- How does Tunisia rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Tunisia ranks 27th out of 194 countries with data for 2025.
- Where does this Tunisia data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).